phone icon (917) 310-3371 Book an Evenity evaluation
Nao Medical

Evenity injection evaluation in NYC

Evenity is a monthly bone-building treatment for postmenopausal women with osteoporosis at high risk for fracture. Evaluation covers fractures and DXA, prior treatment, heart attack and stroke history, calcium and vitamin D, kidney and dental risk, 12 monthly doses, and follow-on antiresorptive therapy.

Nao Medical clinic visit
Nao Medical clinic interior
Nao Medical patient care
Evenity evaluation The current label limits treatment to 12 monthly doses. The full sequence, including the medicine that follows Evenity, should be agreed before the first dose.

Quick answer

Evenity is a monthly bone-building treatment for postmenopausal women with osteoporosis at high risk for fracture. Evaluation covers fractures and DXA, prior treatment, heart attack and stroke history, calcium and vitamin D, kidney and dental risk, 12 monthly doses, and follow-on antiresorptive therapy.

Eligibility and care boundaries

The visit begins with the clinical question and the records that can change the next step.

Very-high fracture risk

Review DXA, recent and prior fractures, falls, other risk factors, failed or intolerable therapies, and whether the labeled population fits.

Cardiovascular review

Heart attack, stroke, vascular disease, blood pressure, smoking, diabetes, lipids, and other risk factors affect the benefit-risk decision.

Calcium, kidney, and dental review

Correct hypocalcemia, review calcium and vitamin D, identify severe renal impairment or dialysis risk, and discuss oral health and planned dental work.

Treatment sequence

Confirm who gives all 12 monthly doses, how missed doses are handled, and which antiresorptive medicine will preserve gains afterward.

How care works

Confirm that Evenity fits

A clinician or bone-health specialist reviews the diagnosis, fracture risk, prior therapy, and whether another treatment should come first.

Complete cardiovascular and laboratory checks

The prescriber reviews heart and stroke history, other cardiovascular risks, calcium, vitamin D, renal status, and dental needs.

Coordinate monthly administration

Staff verify medication acquisition, two-syringe dose handling, an eligible site, trained staff, coverage, and recall for each month.

Move directly to follow-on therapy

After the 12-dose course, the treatment plan ordinarily moves to an antiresorptive medicine to maintain bone-density gains and fracture protection.

Evenity is a time-limited first phase, not a stand-alone long-term plan

Evenity both increases bone formation and decreases bone resorption, but the anabolic effect wanes after 12 monthly doses. The label and Endocrine Society guidance support follow-on antiresorptive therapy when osteoporosis treatment remains necessary.

The boxed warning states that Evenity may increase the risk of heart attack, stroke, and cardiovascular death. It should not be started in someone who had a heart attack or stroke within the previous year, and other cardiovascular risks require an individualized decision.

Hypocalcemia must be corrected before treatment. Patients with severe renal impairment or dialysis have a higher hypocalcemia risk. Oral health, planned dental procedures, jaw symptoms, and new thigh or groin pain also need review.

Call 911 for heart attack, stroke, or severe allergic symptoms

Emergency symptoms include chest pain or pressure, shortness of breath, sudden weakness or numbness, trouble speaking, sudden vision or balance change, facial or throat swelling, or trouble breathing. Report muscle spasms, tingling, confusion, jaw pain, a nonhealing mouth sore, or thigh or groin pain promptly.

Insurance and access

Evenity access can involve specialty medication acquisition, medical-benefit authorization, high-fracture-risk documentation, site-of-care rules, two syringes per dose, and 12 monthly visits. Coverage review does not guarantee approval or cost.

Clinics available for Evenity evaluation and injection coordination

The clinic cards represent evaluation access only. Confirm an eligible administration clinic, two-syringe product supply, laboratory clearance, trained staff, and monthly recall before any injection is scheduled.

Related care

Choose the related care that matches the question you want the clinician to address.

Prolia injection

Compare a long-term antiresorptive pathway with strict six-month continuity.

Reclast infusion

Compare an intravenous bisphosphonate pathway with renal and infusion gates.

Current official medical sources

Medical information was checked against the official sources below on August 1, 2026. The treating clinician confirms the current label and guidance for each patient.

National Library of Medicine DailyMed

Evenity (romosozumab-aqqg) current U.S. prescribing information

Postmenopausal high-fracture-risk indication, two-injection monthly dose, 12-dose limit, cardiovascular boxed warning, calcium, dental, and follow-on treatment needs.

Read the official source

Endocrine Society

Pharmacological management of osteoporosis in postmenopausal women

Treatment sequencing, risk reassessment, denosumab continuity, romosozumab selection, and follow-on antiresorptive therapy.

Read the official source

American Association of Clinical Endocrinology

Clinical Practice Guideline for Postmenopausal Osteoporosis: 2020 Update

Fracture-risk stratification, very-high-risk treatment choices, sequential therapy, monitoring, and transition planning. Current product labels govern drug-specific dosing and contraindications.

Read the official source

Frequently asked questions

Evenity is FDA approved for postmenopausal women with osteoporosis at high risk for fracture, including those with prior osteoporotic fracture, multiple risk factors, or failed or intolerable other therapy.
A full monthly 210 mg dose is two separate 105 mg subcutaneous injections given one after the other by a healthcare provider.
The current label limits use to 12 monthly doses. If treatment is still needed, follow-on antiresorptive therapy should be considered.
The label has a boxed cardiovascular warning and says not to start Evenity if a heart attack or stroke occurred within the preceding year. Other cardiovascular risks also require benefit-risk review.
The clinician reviews calcium, vitamin D, renal status, and other factors based on the history. Low calcium must be corrected before treatment.
Bone-density gains can be lost without a next treatment. An antiresorptive medicine is generally used after the 12-dose course to maintain benefit.
Contact the care team promptly. The label says to administer the missed dose as soon as it can be rescheduled, then continue monthly from the date of the last dose.
Not necessarily. Confirm medication access, an eligible clinic, laboratory clearance, trained staff, and the monthly follow-up plan before treatment.
Nao Medical

Start with the right evaluation

The current label limits treatment to 12 monthly doses. The full sequence, including the medicine that follows Evenity, should be agreed before the first dose.

Medical content checked against the sources above on August 1, 2026.

Health information notice

General information only. This page is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.

Content was updated August 1, 2026 from the sources cited on this page. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.